{"id":56838,"date":"2026-02-11T00:31:29","date_gmt":"2026-02-10T16:31:29","guid":{"rendered":"https:\/\/flcube.com\/?p=56838"},"modified":"2026-02-11T00:31:30","modified_gmt":"2026-02-10T16:31:30","slug":"china-resources-pharma-to-divest-17-87-stake-in-tianmai-bio-for-205-million","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=56838","title":{"rendered":"China Resources Pharma to Divest 17.87% Stake in Tianmai Bio for $205 Million"},"content":{"rendered":"\n

China Resources Pharmaceutical Group Co., Ltd.<\/strong> (HKG:\u202f3320<\/a><\/strong>) announced plans to sell a 17.87% stake<\/strong> in Hefei Tianmai Biotechnology Co., Ltd.<\/strong>, with a minimum listing price of RMB\u202f1.42 billion (USD\u202f205 million)<\/strong>. The divestment follows ORMD-0801’s failed NMPA approval<\/strong> in December\u202f2025, prompting CR Pharma to further reduce exposure<\/strong> to the insulin-focused biopharmaceutical company after multiple stake adjustments since 2016<\/strong>.<\/p>\n\n\n\n

Transaction Overview<\/h2>\n\n\n\n
Element<\/th>Detail<\/th><\/tr><\/thead>
Seller<\/strong><\/td>China Resources Pharmaceutical Group (HKG:\u202f3320)<\/td><\/tr>
Asset<\/strong><\/td>17.87% stake in Hefei Tianmai Biotechnology Co., Ltd.<\/td><\/tr>
Minimum Price<\/strong><\/td>RMB\u202f1.42 billion (USD\u202f205 million)<\/strong><\/td><\/tr>
Valuation Method<\/strong><\/td>Open listing\/auction<\/td><\/tr>
Tianmai Bio Focus<\/strong><\/td>Recombinant human insulin R&D, production, and sales<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n

Shareholding History & Strategic Evolution<\/h2>\n\n\n\n
Timeline<\/th>Event<\/th>CR Pharma Stake<\/th>Strategic Context<\/th><\/tr><\/thead>
2010<\/strong><\/td>Tianmai Bio founded<\/td>\u2013<\/td>Insulin manufacturing focus<\/td><\/tr>
Nov\u202f2016<\/strong><\/td>CR Pharma initial investment<\/td>20%<\/strong><\/td>Entry into diabetes biopharma<\/td><\/tr>
Dec\u202f2017<\/strong><\/td>GMP certification delay; partial exit<\/td>Sold 14.12%<\/strong> at HKD\u202f1.147B (USD\u202f146M)<\/td>Risk management; retained 5.88%<\/td><\/tr>
2020<\/strong><\/td>Increased stake<\/td>23.75%<\/strong> (largest shareholder)<\/td>Recommitment to insulin + ORMD-0801 oral insulin potential<\/td><\/tr>
Dec\u202f2025<\/strong><\/td>ORMD-0801 NMPA rejection<\/td>23.75%<\/strong> maintained until now<\/td>Catalyst for full exit strategy<\/td><\/tr>
Feb\u202f2026<\/strong><\/td>Planned divestment of 17.87%<\/td>Reducing to ~5.88%<\/strong><\/td>Monetization of remaining position<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n

ORMD-0801 Failure & Investment Thesis Breakdown<\/h2>\n\n\n\n
Parameter<\/th>ORMD-0801 Profile<\/th>Failure Impact<\/th><\/tr><\/thead>
Technology<\/strong><\/td>Recombinant human insulin enteric-coated capsule<\/strong> (oral insulin)<\/td>Revolutionary potential vs. injectable insulin<\/td><\/tr>
Origin<\/strong><\/td>Licensed from Israel’s Oramed Pharma<\/strong><\/td>Technology transfer and China-specific development costs<\/td><\/tr>
NMPA Status<\/strong><\/td>Rejected December\u202f2025<\/strong><\/td>Core value driver eliminated; Tianmai Bio reduced to injectable insulin commodity player<\/td><\/tr>
CR Pharma Response<\/strong><\/td>Accelerated divestment<\/strong><\/td>Loss of confidence in Tianmai Bio growth trajectory; capital reallocation to higher-priority assets<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n

Market Context & Strategic Implications<\/h2>\n\n\n\n
Factor<\/th>Strategic Analysis<\/th><\/tr><\/thead>
China Insulin Market<\/strong><\/td>>100 million diabetes patients<\/strong>; intense price competition from domestic (Gan & Lee, Tonghua Dongbao) and multinational (Novo Nordisk, Sanofi) manufacturers<\/td><\/tr>
Tianmai Bio Position<\/strong><\/td>Limited to recombinant human insulin<\/strong> (commoditized, VBP pricing pressure) without ORMD-0801 differentiation<\/td><\/tr>
CR Pharma Portfolio Optimization<\/strong><\/td>Divestment aligns with state-owned enterprise restructuring<\/strong>; proceeds likely redirected to innovative biologics or high-growth therapeutic areas<\/strong><\/td><\/tr>
Valuation Benchmark<\/strong><\/td>USD\u202f205 million for 17.87%<\/strong> implies ~USD\u202f1.15 billion enterprise value<\/strong>; represents downround<\/strong> from 2020 peak expectations post-ORMD-0801 failure<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n

Transaction Outlook<\/h2>\n\n\n\n
Phase<\/th>Activity<\/th>Timeline<\/th><\/tr><\/thead>
Current<\/strong><\/td>Listing announcement; buyer solicitation<\/td>Q1\u202f2026<\/td><\/tr>
Execution<\/strong><\/td>Auction\/bidding process; stake transfer completion<\/td>Q2\u202f2026<\/td><\/tr>
Post-Divestment<\/strong><\/td>CR Pharma retains ~5.88% passive holding or full exit<\/td>2026-2027<\/td><\/tr>
Proceeds Use<\/strong><\/td>Reinvestment into CR Pharma core pharmaceutical or healthcare services businesses<\/td>Ongoing<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n

Forward\u2011Looking Statements<\/strong>
This brief contains forward\u2011looking statements regarding China Resources Pharmaceutical’s stake sale completion, Tianmai Bio valuation in post-ORMD-0801 environment, and CR Pharma capital reallocation strategy. Actual results may differ due to buyer interest levels in insulin manufacturing assets, pricing negotiations, and regulatory developments affecting Tianmai Bio’s remaining product portfolio.-Fineline Info & Tech<\/a><\/p>\n\n\n\n